SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the closing of a $100 million Series B financing. The round was led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others.

"This financing is a testament to the science, strategy, and team we have built at Neomorph, and it provides us with the capital to execute on our most important near-term priorities," said Phil Chamberlain, D.Phil., Co-Founder, President, and Chief Executive Officer of Neomorph. "We remain focused on executing the Phase 1/2 trial of NEO-811 to generate clinical data that will inform continued development, while advancing a broader pipeline of novel molecular glue degraders against targets that have historically been considered undruggable. We are delighted to welcome new partners and grateful for the continued support of our founding investor, Deerfield. We look forward to working together to deliver innovative medicines for patients with ...